Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral tablet for systemic use. It is indicated for severe plaque psoriasis and other keratinization disorders in adult patients.

GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neotigason belongs to the retinoid class and is used to treat disorders of keratinocyte growth and differentiation. - Severe plaque psoriasis: reduces scaling, erythema and plaque thickness. - Other keratinization disorders (e.g., ichthyosis): normalises abnormal skin cell turnover. - Refractory psoriasis: provides an oral systemic option when topical and other systemic agents are insufficient.

Acitretin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry skin and mucous membranes (cheilitis). - Hair thinning or loss. - Elevated triglycerides or cholesterol. - Headache or mild nausea. - Skin sensitivity to sunlight. - Musculoskeletal discomfort.

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes). - Severe hyperlipidaemia. - Pseudotumour cerebri (increased intracranial pressure). - Depression or mood changes. - Bone demineralisation or hyperostosis. - Teratogenic effects (birth defects).

Before initiating therapy, several safety considerations should be addressed. - Pregnancy contraindication: Acitretin is category X and must not be used by pregnant women. - Women of childbearing potential: effective contraception required for at least 3 years after discontinuation. - Liver function: baseline and periodic monitoring of hepatic enzymes is advised. - Lipid profile: check serum triglycerides and cholesterol before and during treatment. - Skeletal health: monitor for signs of bone pain or hyperostosis, especially with long‑term use. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Acitretin can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive retinoid toxicity. - Oral contraceptives: reduced hormonal efficacy, raising pregnancy risk. - Methotrexate: heightened hepatic toxicity when combined. - Warfarin: possible alteration of INR and bleeding risk.

Moderate Interactions (Monitor Closely): - Statins: may exacerbate dyslipidaemia; lipid levels should be checked. - Antifungal agents (e.g., ketoconazole): can increase Acitretin plasma concentrations.